Exchange: NASDAQ·Updated 07:57 PM EDT

GH News

News
all
press releases
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
More News
Guardant Health Announces Approval in Europe of Guardant360 CDx as Companion Diagnostic for AstraZenecas ETCAMAH (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360 CDx has received CE-marking under Europes in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive...
Business Wire
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time...
Business Wire
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal Liquid Biopsy Test for Predicting Recurrence in Melanoma
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective...
Business Wire
Cathie Wood's ARK Invest Buys AVAV Stock Again, Trims GOOGL Stake And Sells Iridium
Cathie Wood's ARK Invest bought another 9,037 AeroVironment shares Tuesday, extending its AVAV buying to a second consecutive session.
Stocktwits
Guardant Healths Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the...
Business Wire
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstractsincluding one mini oral presentationshowcasing advances in methylation-based tumor classification and liquid biopsy technology across...
Business Wire
Business Insider Names Guardant Health One of America's Most Innovative Businesses
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insiders America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research...
Business Wire
Guardant Health Announces Landmark FDA Approval of Guardant360 CDx as Companion Diagnostic for AstraZenecas ETCAMAH (camizestrant) in Advanced Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic...
Business Wire
Guardant Healths Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty...
Business Wire

Advertisement|Remove ads.